![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CHST6 |
Gene summary for CHST6 |
![]() |
Gene information | Species | Human | Gene symbol | CHST6 | Gene ID | 4166 |
Gene name | carbohydrate sulfotransferase 6 | |
Gene Alias | C-GlcNAc6ST | |
Cytomap | 16q23.1 | |
Gene Type | protein-coding | GO ID | GO:0005975 | UniProtAcc | Q9GZX3 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4166 | CHST6 | HCC1 | Human | Liver | HCC | 4.08e-22 | 1.88e+00 | 0.5336 |
4166 | CHST6 | HCC2 | Human | Liver | HCC | 1.80e-31 | 2.05e+00 | 0.5341 |
4166 | CHST6 | HCC5 | Human | Liver | HCC | 1.53e-37 | 2.07e+00 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000679021 | Liver | HCC | sulfur compound metabolic process | 212/7958 | 339/18723 | 5.60e-14 | 3.39e-12 | 212 |
GO:00442722 | Liver | HCC | sulfur compound biosynthetic process | 95/7958 | 148/18723 | 7.89e-08 | 1.58e-06 | 95 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CHST6 | SNV | Missense_Mutation | c.604C>T | p.Arg202Cys | p.R202C | Q9GZX3 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response | |
CHST6 | SNV | Missense_Mutation | novel | c.371N>T | p.Ala124Val | p.A124V | Q9GZX3 | protein_coding | tolerated(0.12) | possibly_damaging(0.45) | TCGA-EO-A3KX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CHST6 | SNV | Missense_Mutation | novel | c.562C>T | p.Leu188Phe | p.L188F | Q9GZX3 | protein_coding | tolerated(0.1) | probably_damaging(1) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CHST6 | SNV | Missense_Mutation | rs768271614 | c.1144N>A | p.Gly382Ser | p.G382S | Q9GZX3 | protein_coding | tolerated(0.88) | benign(0) | TCGA-PG-A916-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CHST6 | SNV | Missense_Mutation | rs569912782 | c.118C>T | p.Arg40Cys | p.R40C | Q9GZX3 | protein_coding | deleterious(0) | probably_damaging(0.91) | TCGA-SJ-A6ZI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CHST6 | insertion | Frame_Shift_Ins | novel | c.295_296insC | p.Val99AlafsTer10 | p.V99Afs*10 | Q9GZX3 | protein_coding | TCGA-AP-A0LH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | PD | ||
CHST6 | SNV | Missense_Mutation | c.652C>A | p.Leu218Met | p.L218M | Q9GZX3 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-44-7670-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD | |
CHST6 | SNV | Missense_Mutation | c.280N>T | p.Asp94Tyr | p.D94Y | Q9GZX3 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-4B-A93V-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
CHST6 | SNV | Missense_Mutation | c.464N>C | p.Arg155Pro | p.R155P | Q9GZX3 | protein_coding | tolerated(0.24) | benign(0.041) | TCGA-75-6206-01 | Lung | lung adenocarcinoma | Male | Unknown | I/II | Unknown | Unknown | SD | |
CHST6 | SNV | Missense_Mutation | c.605N>T | p.Arg202Leu | p.R202L | Q9GZX3 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-75-7027-01 | Lung | lung adenocarcinoma | Male | Unknown | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |